Pharmacokinetics of Clinically Applied Boron-Containing Compounds.
文献摘要
Pharmacology of boron-containing compounds suggests diverse novel advancements within the domain of medical chemistry. In the context of cancer, infectious, dermatological, and inflammatory disorders, boron atoms have distinctive electronic characteristics and the potential for reversible covalent bonding. This review is focused on the pharmacokinetics of boron drugs, including bortezomib, ixazomib, tavaborole, crisaborole, vaborbactam, boric acid, and L-boronophenylalanine. The absorption, distribution, metabolism, and excretion processes of these molecules highlight the decreased persistence of boron drugs compared to other medications; for instance, recent single-cell mass spectrometry data reveal that L-boronophenylalanine exhibits an ultra-rapid intracellular half-life (0.18-0.54 h).A key characteristic of the boron atom is its ability to enhance drug binding to biological targets and improve bioavailability. Furthermore, the kinetic profile of these compounds is unique because there are no human enzymes that catalyze the cleavage of B-C, B-O, or B-N bonds, making their half-life a function of hydro- and lipophilicity. However, Boron drugs can also pose challenges, including chemical instability and oxidative deboronation. The use of prodrugs and topical delivery systems are strategies used to elude these challenges. Thus, the excretion of compounds lacking extensive biotransformation and low potential for drug-drug interactions is a typical attribute of boron-based therapeutics.Current pharmacokinetic and pharmacodynamic methodologies are now paired with physiologically based modeling, which are also instrumental in outcome prediction and in dose optimization for clinical trial applications. Boronated substances, such as novel boron-based proteasome inhibitors, β-lactamase inhibitors, and boron neutron capture therapy agents, signal the initial stages of an evolving line within the scope of biopharmaceutical research. With the exploration of such agents, the need for an understanding of boron kinetics becomes important since it will assist in determining the position of these molecules in future clinical therapeutics.